Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 7/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.40 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10704736 | 0.82 | ESR1 (0.53) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL6273601 | 0.78 | SENP1 (0.50) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL394025 | 0.74 | SENP1 (0.46) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL6058666 | 0.73 | LMNA (0.51) | MGAMGAASIMGAM2CA12 | |
| SCHEMBL522497 | 0.71 | PDXK (0.33) | — | |
| SCHEMBL6058676 | 0.69 | MMP2 (0.42) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL5527905 | 0.69 | ACHE (0.43) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL1457230 | 0.68 | ESR1 (0.71) | ESR1ESR2SENP1CA12CA1 | |
| SCHEMBL306109 | 0.68 | MEN1 (0.35) | — | |
| SCHEMBL28874041 | 0.67 | ESR2 (0.46) | MGAMGAASIMGAM2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0877607-B1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | AVENTIS PHARMA SA (FR) | 2006-11-15 | — | — | EP | disclosed |
| US-6794415-B2 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. (FR) | 2004-09-21 | — | — | US | disclosed |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. | 2004-03-04 | — | — | US | disclosed |
| US-6563008-B2 | Treatment of disorders linked to hypofolliculinemia and of certain estrogen-dependent pathologies such as prostatic adenomas or carcinomas, and of benign tumours of the breast | AVENTIS PHARMA S.A. (FR) | 2003-05-13 | — | — | US | disclosed |
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | LESUISSE DOMINIQUE (FR) | 2002-06-06 | — | — | US | disclosed |
| US-6288126-B1 | Biphenyl compounds and use thereof as oestrogenic agents | AVENTIS PHARMA S.A. | 2001-09-11 | — | — | US | disclosed |
| EP-0877607-A1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | HOECHST MARION ROUSSEL (FR) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997027846-A1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | HOECHST MARION ROUSSEL (FR) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | ESR2, ESR1, CYP19A1 | MGAM 4441/4885GAA 3888/4885SI 3894/4885 |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | CYP19A1, HSD17B11, GPER1 | MGAM 4752/4885GAA 3526/4885SI 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.